MabVax Therapeutics (MBVX) Receives Noncompliant Listing Notification from Nasdaq - Goodman & Nekvasil, P.A., May Recover Investor Losses
Goodman & Nekvasil, P.A., May Recover Investor Losses - MabVax Therapeutics (MBVX) Receives Noncompliant Listing Notification from Nasdaq
MabVax Therapeutics Holdings, Inc. (MBVX), a clinical-stage biotechnology received notice from the Listing Qualifications Department of Nasdaq indicating that the Company is not compliant with Nasdaq Listing Rule 5250(c)(1) which requires the timely filing of periodic reports with the U.S. Securities and Exchange Commission. Goodman & Nekvasil, P.A., a Clearwater, Florida, law firm with a national practice representing victimized investors, continues to investigate brokerage firms that placed elderly retirees and other conservative investors in high-risk investments such as MabVax Therapeutics (MBVX).
Even though stock issued by MabVax Therapeutics (MBVX) had considerable risk, overzealous brokers, brokerage firms and registered investment advisors have nonetheless recommended these types of investments to conservative investors seeking income. We believe that investors MabVax Therapeutics (MBVX) have lost a significant amount of their investment.
Goodman & Nekvasil, P.A., has filed hundreds of cases against brokerage firms selling high-risk investments such as MabVax Therapeutics (MBVX) and has recovered more than $180 million dollars on behalf of victimized investors. We allege in these cases that these investment recommendations were unsuitable for our clients in view of their financial situation, needs and investment objectives. All our cases are handled on a purely contingency fee basis.
You may have the right to recover your losses from the brokerage firm that sold MabVax Therapeutics (MBVX) and other high-risk investments to you. We strongly recommend that you act quickly, however, because statutes of limitation can be short in securities cases.
Kalju Nekvasil, Esq., formerly regional counsel with the NASD, now known as FINRA, has practiced in this area of the law for more than 35 years. We would like to discuss the possibility of your retaining our firm to represent you in an arbitration action.
There is no charge for an evaluation of your case. Further, we handle our cases on a contingency fee basis. This means that unless we recover money for you, we charge no attorney’s fee. Unless you recover any money, you pay us nothing, not even the costs and expenses which the firm will advance on your behalf. Finally, the filing of such a case should not affect your ownership of these investments in any way.
If you incurred losses on your investment in MabVax Therapeutics (MBVX) and/or other high-risk investments and would like your case evaluated by a securities attorney (again, there is no charge for an evaluation and all cases are handled on a purely contingency fee basis), please contact us.
Keywords: Mabvax Therapeutics, Nasdaq, FINRA, Stock, Investment, NASD, MBVX, SEC, Fraud, Attorney, Broker, Brokerage, Firm, Brokerage Firm, Invest, Lawyer, Securities Lawyer, Goodman and Nekvasil, Nekvasil, Goodman, Investor, Investment, Financial, Financial Services, SecuritiesBack to Blogs